Presidio Pharmaceuticals Announces a High Rate of Virologic Response in an Ongoing Phase 2 Hepatitis C Trial of a New All-Oral Combination of Presidioâs PPI-668 With Boehringer Ingelheimâs Faldaprevir and Deleobuvir